Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtideHKSE:03880 +1.82%23 PB Ratio is 1.59 as of Sep. 02, 2026, which is 28% below its 10-year median of 2.20. GuruFocus rates HKSE:03880 with a GF Score™ of 23/100. Among 1,218 Biotechnology companies, Medtide ranks better than 72.91% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-02), Medtide's share price is HK$21.22. Medtide's Book Value per Share for the quarter that ended in Dec. 2025 was HK$13.35. Hence, Medtide's PB Ratio of today is 1.59.
Good Sign:
Medtide Inc stock PB Ratio (=1.61) is close to 2-year low of 1.6.
The historical rank and industry rank for Medtide's PB Ratio or its related term are showing as below:
HKSE:03880'
s PB Ratio Range Over the Past 10 Years
Min: 1.56 Med: 2.2 Max: 16.93
Current: 1.59
During the past 5 years, Medtide's highest PB Ratio was 16.93. The lowest was 1.56. And the median was 2.20.
HKSE:03880's PB Ratio is ranked better than 72.91% of 1218
companies
in the Biotechnology industry
Industry Median: 2.945
vs HKSE:03880: 1.59
During the past 12 months, Medtide's average Book Value Per Share Growth Rate was 414.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 97.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Medtide was 97.90% per year. The lowest was 38.30% per year. And the median was 68.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Medtide PB Ratio Related Terms
Medtide PB Ratio Historical Data
* Premium members only.
The historical data trend for Medtide's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03880 vs VRTX, REGN, MRNA: PB Ratio Comparison
For the Biotechnology subindustry, Medtide's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtide PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medtide's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medtide's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Medtide's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medtide (HKSE:03880) has a PB Ratio of 1.59 as of Sep. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medtide and its competitors. This is 28% below median its historical median of 2.20. Over the past decade, Medtide's PB Ratio has ranged from 1.56 to 16.93. According to the industry distribution chart, Medtide ranks #330 out of 1218 companies in the Biotechnology industry, placing it in the top 27.1%.
Is Medtide's PB Ratio too high?
Medtide's current PB Ratio of 1.59 is 28% below median its 10-year median of 2.20. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 16.93. The Biotechnology industry median PB Ratio is 2.95. Medtide's value of 1.59 is 46% below this industry median. Based on the distribution chart, Medtide ranks #330 out of 1218 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medtide has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medtide ranks #330 out of 1218 companies for PB Ratio. This puts Medtide in the upper half of its industry. The industry median PB Ratio is 2.95. Medtide's value of 1.59 is 46% below this benchmark. Historically, Medtide's own PB Ratio has ranged from 1.56 to 16.93 over the past decade. While the company's 10-year median is 2.20 vs. the industry median of 2.95, Medtide has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,218 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtide's current PB Ratio of 1.59 is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medtide and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtide's current PB Ratio is 1.59, which is 28% below median its own 10-year median of 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (HKSE:03880) has a current PB Ratio of 1.59. The current PB Ratio is 1.59, which is 28% below median its 10-year median of 2.20 and 46% below the Biotechnology industry median of 2.95. Medtide's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medtide (HKSE:03880), the current PB Ratio is 1.59 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
23GF Score
Get the complete analysis for HKSE:03880
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03880 has been successfully added to your 
